Completing treatment for breast cancer is an important and emotional milestone, bringing a deep sense of relief, hope, and renewed strength. Yet, it’s also natural to feel concerned about the ...

When multiple myeloma returns after a period of remission, treatment plans often need to be adjusted because the cancer may have become resistant to previous medications. Doctors determine the most ...

Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, or CAR-T cell therapy. Over time, the engineered immune ...

For most children diagnosed with medulloblastoma, the most common malignant pediatric brain tumor, survival rates are encouraging. But for a subset, remission is not the end of the story. Roughly 30% ...

New therapies for multiple myeloma are dramatically improving prognosis and extending survival. Better disease control is prolonging remission and allowing patients to live without any sign of disease ...

An innovative blood cancer treatment regime could extend remission by seven months on average, according to a clinical trial led by the University of Leeds. Myeloma, a blood cancer that accounts for 1 ...

Initial expectations of cure after six cycles of ABVD were upended by repeated complications, underscoring how early prognostic framing can diverge sharply from real-world toxicity and disease control ...

Last January, I went in for my regular biannual oncology check. When I made the appointment, I wasn’t expecting anything to ...

Worries have persisted that cancer survivors in remission might face increased recurrence risk when treated with biologic drugs for autoimmune disease. This Danish study of rheumatoid arthritis ...

For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows that 1 ...